U.S. Point of Care Infectious Disease Testing Market Size, Share, and Trends 2024 to 2033

U.S. Point of Care Infectious Disease Testing Market (By Disease: Pneumonia Or Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), TB and Drug Resistant TB POC, Influenza/Flu POC, HIV POC, Others; By End-user: Hospitals, Clinics, Home, Assisted Living Healthcare Facilities, Laboratories, Others) - Regional Outlook and Forecast 2024 to 2033

  • Last Updated : June 2024
  • Report Code : 4461
  • Category : Healthcare

U.S. Point of Care Infectious Disease Testing Market Size and Companies

The U.S. point of care infectious disease testing market size was USD 1.9 billion in 2023, calculated at USD 2.06 billion in 2024 and is expected to reach around USD 4.59 billion by 2033. The market is expanding at a solid CAGR of 9.30% over the forecast period 2024 to 2033. The U.S. point of care infectious disease testing market is driven by the rising need for quick diagnosis to start therapy early.

U.S. Point of Care Infectious Disease Testing Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

U.S. Point of Care Infectious Disease Testing Market Key Takeaways

  • By disease, the influenza/flu segment has held a major revenue share of 24.42% in 2023.
  • By disease, the respiratory syncytial virus (RSV) segment is the second largest in the market in 2023.
  • By end-user, the hospitals segment dominated market with the largest revenue share of 38.56% in 2023.

Market Overview

Since infections can spread from person to person and throughout populations, pathogenic microbes pose a threat to public health and the economy and cause infectious diseases. Effective diagnostic tools are required to deliver precise and timely assistance for case identification, transmission disruption, and proper treatment administration. Point of care (POC) tests function as a personal "radar" and deliver actionable data close to the patient.

Point of care tests (POCT) detect a range of biomarkers associated with infectious disorders, such as viral particles, nucleic acids, proteins, and antibodies. These include compact molecular diagnostic systems, lateral flow assays, microfluidics, plasmonic technologies, and paper-based assays, among others. POCTs provide the cornerstone of infectious illness diagnosis and therapy that is "patient centralized."

Point-of-care testing (POCT) has become increasingly popular due to changes in health management models, advances in interdisciplinary technologies, and growing public awareness of disease prevention. Numerous affordable, lightweight, and quick POCT devices have been developed to support patient prognostic improvement, disease control, and health management.

U.S. Point of Care Infectious Disease Testing Market Data and Statistics

  • In May 2023, Sensible Diagnostics created a tiny, inexpensive sample-to-answer device to complete PCR in ten minutes. The company plans to introduce its system with affordable test cartridges in early 2024, first concentrating on point-of-care testing for infectious diseases.
  • According to the World Health Organization, by the end of 2022, an estimated 39.0 million people were HIV positive.

U.S. Point of Care Infectious Disease Testing Market Growth Factors

  • Improved patient outcomes and faster treatment are made possible by more rapid diagnosis, which fuels market expansion.
  • Self-testing is becoming increasingly common, and point-of-care (POC) diagnostics provide easy home diagnosis choices.
  • Infectious diseases are spreading more widely due to increased travel and worldwide population, necessitating quicker testing methods.
  • New technologies facilitate remote diagnosis and monitoring and increase market adoption, such as POCT (point-of-care testing) facilitated by telehealth.
  • Non-healthcare professionals can use POC tests in environments with low resources, which can increase access to diagnostics in underdeveloped nations.

U.S. Point of Care Infectious Disease Testing Market Scope

Report Coverage Details
Market Size in 2023 USD 1.9 Billion
Market Size in 2024 USD 2.06 Billion
Market Size by 2033 USD 4.59 Billion
Market Growth Rate from 2024 to 2033 CAGR of 9.30%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Disease and End-user

 

U.S. Point of Care Infectious Disease Testing Market Dynamics

Driver

Latest trends of consumer-centric services coupled with high demand for portable and rapid testing devices

Consumer-centric services prioritize patient's wants and preferences and place greater emphasis on user experience, convenience, and accessibility. This translates into an increasing need for testing solutions in infectious disease testing that are simple to use, yield fast findings, and can be carried out outside of conventional healthcare facilities like clinics and hospitals.

Numerous point-of-care testing devices that address these needs have been developed due to the growth of consumer-centric services. Because these devices are frequently small, lightweight, and easy to use, people can conduct tests independently or with little help from medical experts. This accessibility facilitates early diagnosis and treatment of infectious diseases and gives people more control over their healthcare. This drives the growth of the U.S. point of care infectious disease testing market.

Restraint

Limitations associated with point of care testing

The former frequently show lower sensitivity and specificity when comparing point-of-care testing to laboratory-based assays. This indicates that false-positive and false-negative test findings are more frequent, which might result in incorrect diagnosis and treatment. The reduced accuracy of POCT can be a significant problem in the case of infectious diseases, where precise diagnosis is essential for patient treatment and public health. The operator's proficiency and expertise can impact the accuracy of point-of-care tests.

Errors and incorrect diagnoses can be caused by improper procedures or unskilled people interpreting the results. Although it might be resource-intensive, ensuring healthcare providers using POCT devices have the necessary training and proficiency is crucial.

Opportunity

Need for better and regular monitoring systems in near-patient settings

Infectious disease prevalence remains a concern for world health. Epidemics of HIV/AIDS, hepatitis, influenza, and sexually transmitted infections (STIs) in the United States underscore the need for prompt and efficient diagnostic services. New point-of-care test instruments that provide quick and precise findings are the product of technological breakthroughs.

These gadgets are becoming more affordable, portable, and user-friendly, making them appropriate for usage in various near-patient environments, including community health centers, clinics, and emergency rooms. This opens an opportunity for the growth of the U.S. point of care infectious disease testing market.

U.S Point of Care Infectious Disease Testing Market Revenue (US$ Mn), By By Disease, 2020 to 2023

By Disease 2020 2021 2022 2023
Pneumonia or Streptococcus-associated infections 253.68 268.4 290.44 314.52
Respiratory syncytial virus (RSV) POC 338.24 355.14 381.36 410.21
TB and drug-resistant TB POC 193.64 203.12 217.92 234.64
Influenza/Flu POC 374.7 395.36 426.64 465.85
HIV POC 126.01 133.19 143.98 155.6
Others (Clostridium difficile POC, HBV POC, etc.) 271.96 286.41 308.49 327.81

 

Disease Insights

The influenza/flu segment dominated in the U.S. point of care infectious disease testing market in 2023. The risk of influenza outbreaks, particularly pandemics from novel strains, has increased understanding of the significance of quick and precise diagnostic testing. Healthcare facilities, such as clinics, urgent care centers, and hospitals, have progressively embraced POC testing for influenza to improve their preparedness and response capacities for outbreaks in response to public health concerns. POC testing for influenza enhances patient care and saves money by maximizing healthcare resources and lowering total healthcare expenses.

POC testing conserves healthcare resources, such as staff time, laboratory equipment, and consumables, and results in cost savings for healthcare organizations and payers by optimizing diagnostic workflows and reducing needless laboratory testing.

The respiratory syncytial virus (RSV) segment is the second largest in the U.S. point-of-care infectious disease testing market in 2023. RSV significantly contributes to respiratory tract infections, especially in young children and newborns. Adults are also susceptible, particularly the elderly and those with weakened immune systems. The rising frequency of RSV infections raises the need for quick and precise diagnostic procedures for prompt management and treatment. RSV infections have the potential to cause severe respiratory diseases, such as pneumonia and bronchiolitis, especially in susceptible groups like young children, the elderly, and people with underlying medical disorders. Point-of-care testing to detect RSV infections early is essential for starting treatments on time and avoiding consequences.

  • In May 2023, the world's first vaccination against the Respiratory Syncytial Virus (RSV) was licensed in the United States, capping a decades-long quest to shield susceptible individuals from the widespread disease.

U.S Point of Care Infectious Disease Testing Market Revenue (US$ Mn), By By End User 2020-2023

By End User 2020 2021 2022 2023
Hospitals 595.25 628.41 678.53 735.96
Clinics 285.42 298.99 320.34 344.82
Home 138.84 145.45 155.83 166.98
Assisted Living Healthcare Facilities 155.2 164.33 177.95 192.77
Laboratories 250.98 265.5 287.26 310.44
Others (Ambulatory Surgical Centers, etc.) 132.55 138.94 148.94 157.65


End-user Insights

The hospitals segment dominated in 2023 and expected to sustain the dominance in the U.S. point of care infectious disease testing market. In addition to diagnostic tests, hospitals provided treatment, follow-up care, and monitoring for infectious diseases. Their status as the go-to option for managing contagious diseases was further cemented by their all-encompassing approach, which guaranteed continuity of care and improved patient outcomes. Because of their significant resources and strong infrastructure, hospitals were well-suited to manage the challenges of testing for infectious diseases. At the point of care, they could perform quick and precise diagnostic tests because of the facilities, tools, and staff they had on hand. This allowed for quick decision-making and prompt interventions.

U.S. Point of Care Infectious Disease Testing Companies

U.S. Point of Care Infectious Disease Testing Market Companies

  • Beckton Dickinson
  • Roche
  • Biomerieux
  • Siemens
  • Bio-rad
  • Chembio Diagnostic Systems
  • Quidel Corporation
  • Abbott

Recent Developments

  • In March 2024, in spring 2024, the City University of New York (CUNY) Institute for Implementation Science in Population Health (ISPH) and the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) will launch a critical two-year prospective epidemiologic study in partnership with Pfizer to monitor acute respiratory infections nationwide.
  • In February 2022, The World Health Organization (WHO) approved Trinity Biotech plc's new HIV screening tool, Trin Screen HIV.

Segments Covered in the Report

By Disease

  • Pneumonia Or Streptococcus Associated Infections
  • Respiratory Syncytial Virus (RSV)
  • TB and Drug Resistant TB POC
  • Influenza/Flu POC
  • HIV POC
  • Others

By End-user

  • Hospitals
  • Clinics
  • Home
  • Assisted Living Healthcare Facilities
  • Laboratories
  • Others

Frequently Asked Questions

The U.S. point of care infectious disease testing market size is expected to increase USD 4.59 billion by 2033 from USD 1.9 billion in 2023.

The U.S. point of care infectious disease testing market is anticipated to grow at a CAGR of over 9.30% between 2024 and 2033

The major players operating in the U.S. point of care infectious disease testing market are Beckton Dickinson, Roche, Biomerieux, Siemens, Bio-Rad, Chembio Diagnostic Systems, Quidel Corporation, Abbott, and Others.

The driving factors of the U.S. point of care infectious disease testing market are the latest trends of consumer-centric services coupled with high demand for portable and rapid testing devices.

North America region will lead the U.S. point of care infectious disease testing market during the forecast period 2024 to 2033.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client